BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent Patients - Biomarin Pharmaceutical (NASDAQ:BMRN)
3 Articles
3 Articles
BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent Patients - Biomarin Pharmaceutical (NASDAQ:BMRN)
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released topline data from the Phase 3 PEGASUS trial evaluating Palynziq (pegvaliase-pqpz) compared to diet alone in 55 adolescents aged 12-17 with phenylketonuria (PKU). PKU is a rare, inherited metabolic disorder that prevents the body from breaking down the amino acid phenylalanine. Untreated phenylketonuria can lead to brain damage, intellectual disabilities, behavioral symptoms or seizures. The pri…
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage